What Tepezza Treats: Main Uses and Benefits

The medication is commonly used in the therapeutic management of Thyroid Eye Disease (TED) in adults, an autoimmune condition causing inflammation and structural changes behind the eyes, and is applied across domains where additional symptomatic support is needed. This condition is often characterized by pronounced symptoms, including eye bulging (proptosis), impaired eye alignment (diplopia), and active inflammation manifested as orbital pain, redness, and swelling.

The treatment is generally applied in situations where symptoms are clinically significant or in situations involving significant functional stress on the orbital structures. It is relevant for easing symptoms that interfere with daily functioning and managing active inflammation. This approach supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Relief for Ocular Functional Strain

The medication is applicable across conditions presenting with recurrent or episodic manifestations that produce significant symptomatic burden. It is particularly used when the structural symptoms, like proptosis, create noticeable interference with functional stability, and when active inflammation causes distressing manifestations. It may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Regulatory References

1. European Medicines Agency (EMA) Tepezza Overview

Eligibility Map: Who can and cannot use Tepezza — official regulatory information

Eligibility Scope
Populations for whom use is allowed (as stated in label):	Adults (mathbf18 years of age and older) with Thyroid Eye Disease who meet thyroid function criteria.
Populations for whom use is not recommended (if applicable):	Pediatric patients, as safety and efficacy in those under mathbf18 years of age is not established.
Populations for whom use is contraindicated:	Patients with known hypersensitivity to the active substance or excipients; Females who are pregnant.
Age-related eligibility rules:	Approved only for adults; Use is restricted in adolescents and children.

---

Eligibility Classifications (High-level)
Eligibility severity classification (as defined in official documents):	Contraindicated (Pregnancy, Hypersensitivity); Not Established (Pediatric Use); Conditional Use (Comorbidities).
Eligibility-context constraints (as defined in official documents):	Use requires compliance with mandated contraception; Use is conditional upon appropriate glycemic control for diabetic patients.

---

Resulting Eligibility Structure

Official eligibility statements:

• Use is contraindicated in pregnancy and in patients with known hypersensitivity to the medicine.
• The medicine is approved only for adults with Thyroid Eye Disease, with no established use in the pediatric population.
• Females of reproductive potential must use effective contraception during treatment and for mathbf6 months following the final dose.
• Patients with pre-existing diabetes must be under appropriate glycemic control prior to and throughout the course of treatment.
• Patients with Inflammatory Bowel Disease (IBD) require monitoring for disease exacerbation, which may necessitate discontinuation.

Connection to the overall eligibility profile The regulatory profile establishes mandatory boundaries, explicitly limiting approval to the adult population and prohibiting use during pregnancy. Eligibility for patients with comorbidities like diabetes and IBD is defined through strict conditional use rules, requiring pre-treatment management and continuous monitoring as specified in the official label.

Tepezza (teprotumumab-trbm) is a biologic medication that works by blocking the insulin-like growth factor 1 receptor (IGF-1R). Because of this mechanism, it has a limited number of known drug interactions compared to many small-molecule medications. However, it is essential to inform your healthcare provider about all medicines you take, including prescription and over-the-counter drugs, vitamins, and herbal supplements.

Medicines that May Affect Hearing

Tepezza is known to be associated with hearing impairment, including hearing loss and tinnitus (ringing in the ears). Taking Tepezza with other medications that are also known to cause ototoxicity (damage to the ear, potentially leading to hearing issues) could increase the risk or severity of hearing problems.

Key classes of medications to discuss with your doctor include:

Drug Class	Examples
Aminoglycoside antibiotics	Gentamicin, Amikacin, Tobramycin
Platinum-based chemotherapy	Cisplatin, Carboplatin
Loop Diuretics (at high doses)	Furosemide, Bumetanide

Your doctor will weigh the potential risks and benefits if you must take Tepezza concurrently with an ototoxic medicine. Routine hearing checks may be performed before, during, and after treatment to monitor for changes.

Medicines that Affect Metabolism

Tepezza is a protein and is eliminated by the body through natural protein catabolism, not through the liver enzymes (cytochrome P450 system) that metabolize most other drugs. Therefore, it is unlikely to interact with medicines that either induce or inhibit these liver enzymes.

Targeted IGF-1R Blockade and Cellular Clearance

The drug is a monoclonal antibody that acts as a specific antagonist by binding to the extracellular domain of the Insulin-like Growth Factor-1 Receptor ( IGF-1R) on the surface of orbital fibroblasts. This binding physically blocks the receptor's activation and simultaneously triggers its internalization and degradation, promoting the clearance of the receptor from the cell surface.

Disruption of Pathogenic Signaling Cascades

The IGF-1R is functionally linked to the Thyroid-Stimulating Hormone Receptor ( TSHR) within the orbital fibroblasts. By inhibiting the IGF-1R component, Teprotumumab disrupts this entire synergistic signaling cascade, modulating the downstream physiological responses driven by the overactive pathway.

Inhibition of Tissue Expansion Mediators

The functional blockade of the IGF-1R/ TSHR pathway leads to the suppression of specific cellular activities. This includes the reduction of pro-inflammatory cytokine secretion and the inhibition of both adipogenesis (fat cell differentiation) and the production of excessive glycosaminoglycans (like Hyaluronic Acid), which mediate fluid accumulation and tissue expansion. This mechanism contributes to the attenuation of inflammation and the reduction of tissue volume in the orbital tissue.

How Tepezza Is Administered

Tepezza (teprotumumab-trbw) is a medicine administered solely through intravenous (IV) infusion.

---

Dosing and Schedule

Tepezza is administered in a specific sequence of doses based on the patient's actual body weight.

Infusion Number	Dose per Kilogram of Body Weight
First Infusion	10 mg/kg
Subsequent Infusions (2 through 8)	20 mg/kg

The full course of treatment consists of 8 total infusions, each administered once every three weeks.

---

Administration Procedure

Tepezza is supplied as a lyophilized powder and requires specific preparation before infusion. It must be reconstituted with sterile water and then diluted in 0.9% Sodium Chloride Injection, USP (Normal Saline). The solution must be handled gently; do not shake the vial.

The administration rate is time-sensitive:

• Infusions 1 and 2 must be administered over a minimum of 90 minutes.
• Infusions 3 through 8 may be reduced to a minimum of 60 minutes if the first two infusions were tolerated well, otherwise they must remain 90 minutes.

Important Administration Constraints: Tepezza must not be administered as an IV push or bolus, and it should not be co-infused with any other agents. There are no explicit instructions concerning administration in relation to meals.

Evidence for Use in Active Thyroid Eye Disease (TED)

Teprotumumab was studied for symptoms change over time in people with Active Thyroid Eye Disease (TED). This refers to the phase of the condition with high scores on inflammatory scales. The foundational evidence includes randomized, double-masked, placebo-controlled trials (RCTs). In these high-quality studies, participants are assigned by chance to receive either the medicine or an inactive substitute (placebo). These studies monitored specific outcomes related to physical discomfort and structural measurements, including proptosis (eye bulging) and the Clinical Activity Score (CAS) outcome.

Reports from these core studies described patterns in the measured outcomes for proptosis and the CAS score at the end of the initial 24-week treatment course in the teprotumumab group compared to the placebo group. Research also described outcomes measured during the study period for functional vision, such as diplopia (double vision), and quality of life scores.

---

Evidence for Use in Chronic, Longstanding TED

Research has also explored the role of teprotumumab in studies involving individuals with Chronic or Longstanding TED. This group includes people who have experienced the condition for several years and whose disease activity (CAS) has stabilized at a low level, but who still live with structural symptoms. For this population, studies monitored outcomes reflecting daily functioning or activity level and focused on the key structural measure of proptosis through a dedicated randomized, placebo-controlled trial.

---

Durability and Long-Term Follow-up Evidence

Initial clinical research typically uses short-term follow-up durations—most commonly 24 weeks—for initial comparisons. To investigate durability, open-label extension studies were conducted, where participants were observed for extended periods, up to approximately two years after the last treatment infusion. These studies were applied in research contexts involving fluctuating or unstable symptoms to determine whether the measured response was maintained over subsequent months without the need for additional treatments for TED.

---

Key Limitations and Research Gaps

Research into teprotumumab has established a body of evidence, yet, as with any medical research, data are still emerging and certain limitations exist. One key limitation is that follow-up durations were limited in the initial double-masked studies; multi-year patterns are not fully characterized by controlled evidence. Furthermore, in the study focusing on individuals with chronic TED, the trial's design provided limited insight into changes in certain functional measures, such as diplopia, due to the small number of participants who had that symptom at the start of the study. Individual outcomes may vary significantly from the group patterns reported in the research.

Key Studies & References

1. Efficacy and Safety of Teprotumumab in Chronic Thyroid Eye Disease (Phase 4 Chronic TED Trial)
2. Long-term Maintenance of Response After Teprotumumab Treatment in Thyroid Eye Disease (OPTIC-X Extension Study)

Common questions about Tepezza (FAQ)

Q: What is Tepezza used to treat?

A: According to the official product information, Tepezza (teprotumumab-trbm) is approved to treat Thyroid Eye Disease (TED). TED is an autoimmune condition that causes inflammation and damage behind the eye. It is indicated to reduce proptosis (eye bulging) in patients with this disease.

Q: What is the active ingredient in Tepezza?

A: The active ingredient in Tepezza is teprotumumab-trbm. Regulatory documents state that this is a fully human monoclonal antibody. It works by targeting and blocking the Insulin-like Growth Factor-1 Receptor (IGF-1R), which is involved in the disease process of Thyroid Eye Disease.

Q: How is Tepezza given?

A: Studies and official information indicate that Tepezza is administered as an intravenous (IV) infusion. This means the medicine is delivered directly into a vein. The infusions are typically given by a healthcare professional in a medical setting.

Q: How long does a course of treatment with Tepezza usually last?

A: According to the official product information, a full course of treatment with Tepezza consists of eight total infusions. The recommended treatment course involves a set schedule over several months.

Q: Can I take Tepezza if I have diabetes?

A: Official regulatory documents indicate that Tepezza can cause elevated blood sugar, or hyperglycemia, in patients with pre-existing diabetes or glucose intolerance. For patients with pre-existing diabetes, the official product information advises that closer monitoring and adjustment of blood sugar management may be required during treatment.

Q: What happens if I miss a scheduled dose of Tepezza?

A: Regulatory documents state that if a patient misses a scheduled infusion, a healthcare provider should administer the missed dose as soon as possible. If a dose is missed, a healthcare provider determines the appropriate time to administer the dose and how to adjust the remaining schedule.

Q: Can Tepezza affect hearing?

A: Studies and official information indicate that Tepezza has been associated with hearing problems, also known as otologic adverse reactions. These can include hearing impairment, deafness, and ringing in the ears (tinnitus). Official product information notes that, in some cases, hearing impairment associated with the treatment did not fully resolve after stopping the medication.

Q: Is there a risk of infusion reactions with Tepezza?

A: Official product information states that infusion reactions are a possible risk with Tepezza. These reactions can occur during the infusion or within 1.5 hours afterward. Symptoms noted in regulatory documents include headache, feeling tired (fatigue), rapid heart rate (tachycardia), and shortness of breath (dyspnea).

Q: Should I stop taking Tepezza if I am pregnant or plan to be?

A: Regulatory documents indicate that Tepezza may cause fetal harm when administered to a pregnant patient. Because regulatory documents indicate that the drug may cause fetal harm, patients who are pregnant, or planning to become pregnant, are advised to discuss the potential risks with their doctor.

Q: What are common side effects reported in official studies?

A: According to the official product information and clinical studies, the most common side effects are muscle spasm, feeling sick (nausea), hair loss (alopecia), fatigue, and diarrhea. Other common side effects noted in regulatory sources include headache, dry skin, and changes in taste (dysgeusia).

Storage and Handling of Tepezza

Tepezza (teprotumumab-trbw) must be stored according to strict regulatory conditions to maintain the stability of the lyophilized powder for infusion.

• Unopened Vials: Store in a refrigerator at a temperature between 2 C to 8 C. Vials must be kept in the outer carton to protect the contents from light and must not be frozen.
• Prepared Solution Stability: After reconstitution and dilution, the solution must be used within a total combined time of 4 hours at room temperature (25 C) or up to 48 hours under refrigeration (2 C to 8 C). The solution must not be frozen and should be inspected for particulate matter before use.
• Child Safety: The product must be stored out of the sight and reach of children.
• Disposal: All vials and any unused contents must be discarded according to local regulations for pharmaceutical waste.